Document Detail


Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials.
MedLine Citation:
PMID:  20924643     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Background Cardiotoxicity of Molecular Targeted Therapies (MTT) is poorly understood and is being investigated among patients with metastatic solid tumours. The frequency of cardiac events among patients receiving MTT has been evaluated in various ways, particularly troponin elevations. Patients and methods We prospectively evaluated cardiotoxicity among patients included in Phase 1 trials receiving molecular targeted therapies (MTT) for a metastatic solid tumour. At baseline, all patients were examined before the first cycle and monitored including a clinical examination, ECG and troponin I measurement. A trans-thoracic echocardiography was performed at baseline and before each cycle. Patients were enrolled in different trials investigating : an anti-VEGF monoclonal antibody, anti-VEGFR tyrosine kinase inhibitors, and a kinesin inhibitor. Results Among the 90 patients evaluated, 10 (11%) experienced chest pain and troponin I elevation (n = 2,20%) or asymptomatic troponin I elevation (n = 8, 80%) during follow-up. All patients were re-evaluated at the time of symptoms or troponin I elevation with trans-thoracic echocardiography, cardiac magnetic resonance and coronary angiography. All except one patient, had a normal LVEF during their re-evaluation. One patient exhibited ECG changes (T wave inversion). No QTc interval prolongation was found. On cardiac magnetic resonance, no late gadolinium myocardial enhancement was observed. All coronary angiographies were normal (no occlusion, or coronary stenosis >50%). All patients received beta blockers and aspirin. All Patients were re-challenged with the study drug and no cardiotoxicity was observed during follow up. Conclusion Troponin elevations are frequent among patients receiving molecular targeted therapies. Re-challenging these patients after a careful evaluation and under medical treatment seems to be possible. The mechanism underlying troponin elevations does not seem to be associated with coronary occlusion nor with toxic myocarditis.
Authors:
Stephane Ederhy; Christophe Massard; Ghislaine Dufaitre; Ratio Balheda; Catherine Meuleman; Carlos Gomez Rocca; Hassane Izzedine; Ariel Cohen; Jean-Charles Soria
Related Documents :
18693603 - Exercise tolerance test: a comparison between true positive and false positive test res...
9853193 - Why we should attempt to eliminate (silent and symptomatic) ischemia in patients with c...
3981193 - Phrenic nerve conduction time in guillain-barré syndrome.
Publication Detail:
Type:  Journal Article     Date:  2010-10-06
Journal Detail:
Title:  Investigational new drugs     Volume:  30     ISSN:  1573-0646     ISO Abbreviation:  Invest New Drugs     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-02-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309330     Medline TA:  Invest New Drugs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  611-5     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Saint-Antoine University and Medical School, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antiangiogenic properties of an unusual benzo[k,l]xanthene lignan derived from CAPE (Caffeic Acid Ph...
Next Document:  Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic ...